ALNY vs CAPR · P/E 76, rev $1.29B vs $1.62B cap
Alnylam Pharmaceuticals Inc (ALNY) versus Capricor Therapeutics Inc (CAPR) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Capricor Therapeutics Inc (CAPR) is a biotechnology company listed on NASDAQ.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported CAPR revenue for 2025-12-31 was $0. Net income was -$105.0M. CAPR currently screens at market cap $1.62B.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. CAPR currently screens at market cap $1.62B.
Not investment advice. Open the ALNY and CAPR stock pages for the full models.
Not investment advice.